Dynavax Technologies Co. (NASDAQ:DVAX) – Analysts at William Blair increased their FY2017 earnings per share estimates for Dynavax Technologies in a research note issued to investors on Monday. William Blair analyst Y. Xu now anticipates that the biopharmaceutical company will post earnings of ($1.70) per share for the year, up from their previous estimate of ($1.71). William Blair also issued estimates for Dynavax Technologies’ Q1 2018 earnings at ($0.43) EPS, Q2 2018 earnings at ($0.41) EPS, Q3 2018 earnings at ($0.38) EPS, Q4 2018 earnings at ($0.29) EPS and FY2018 earnings at ($1.50) EPS.

DVAX has been the topic of a number of other reports. Cowen restated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a research note on Friday, November 3rd. Cantor Fitzgerald started coverage on Dynavax Technologies in a research note on Friday, September 15th. They issued an “overweight” rating and a $24.00 price target on the stock. BidaskClub cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Royal Bank of Canada restated an “outperform” rating and issued a $28.00 price target (up from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. Finally, ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Dynavax Technologies has an average rating of “Hold” and a consensus target price of $25.17.

Shares of Dynavax Technologies (NASDAQ DVAX) opened at $16.85 on Wednesday. Dynavax Technologies has a 52 week low of $3.70 and a 52 week high of $24.45. The firm has a market capitalization of $1,020.00, a price-to-earnings ratio of -8.60 and a beta of 1.31.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. During the same period last year, the firm earned ($0.90) earnings per share. Dynavax Technologies’s quarterly revenue was down 68.8% on a year-over-year basis.

In other news, VP David Louis Johnson sold 3,092 shares of Dynavax Technologies stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $18.60, for a total transaction of $57,511.20. Following the sale, the vice president now owns 7,780 shares in the company, valued at $144,708. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert Coffman sold 7,500 shares of Dynavax Technologies stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total value of $141,750.00. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of DVAX. Cubist Systematic Strategies LLC grew its holdings in shares of Dynavax Technologies by 54.5% during the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,700 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Dynavax Technologies by 18.5% during the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares during the last quarter. Wall Street Access Asset Management LLC purchased a new position in shares of Dynavax Technologies during the second quarter worth about $124,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Dynavax Technologies by 474.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 5,880 shares during the last quarter. Finally, Family Management Corp grew its holdings in shares of Dynavax Technologies by 72.7% during the second quarter. Family Management Corp now owns 19,000 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 8,000 shares during the last quarter. Institutional investors and hedge funds own 70.54% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/dynavax-technologies-co-dvax-forecasted-to-earn-fy2017-earnings-of-1-70-per-share/1802207.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.